AstraZeneca Confident For Next Decade Despite Upcoming Patent Cliff

Misses Q4 Sales Consensus Estimate

 
• By Ayisha Sharma

The UK major believes it can maintain growth trajectory through novel combinations regimens and pipeline diversification despite the anticipated expiration of several blockbuster drug patents over the next decade.  

Grey cliff against a light yellow sky, mountains in background
Soriot Remained Unfazed By The Prospect Of A Patent Cliff • Source: Shutterstock

More from Earnings

More from Business